|
original article |
Journal |
Date |
Title |
Authors All Authors |
1 |
[GO] |
Antiviral Therapy |
2021―Mar―11 |
The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review |
Jienchi Dorward, Oghenekome Gbinigie, Ting Cai, Nia W Roberts, Nigel Garrett, Gail Hayward, Christopher C Butler |
2 |
[GO] |
Antiviral Therapy |
2021―Feb―22 |
COVID-19 and hepatitis B infection |
Saleh A Alqahtani, Maria Buti |
3 |
[GO] |
Antiviral Therapy |
2021―Jan―18 |
Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity |
Mattia Trunfio, Elena Salvador, Alberto Gaviraghi, Sabrina Audagnotto, Letizia Marinaro, Ilaria Motta, et al. (+6) Riccardo Casciaro, Valeria Ghisetti, Carmen Fava, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno |
4 |
[GO] |
Antiviral Therapy |
2020―Aug―03 |
Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system |
Michael A Jarvis, Frederick A Hansen, Kyle Rosenke, Elaine Haddock, Christopher Rollinson, Simon Rule, et al. (+3) Graham Sewell, Andrew Hughes, Heinz Feldmann |
5 |
[GO] |
Antiviral Therapy |
2020―Jun―26 |
SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection |
Elise J Smolders, Lindsey HM te Brake, David M Burger |
6 |
[GO] |
Antiviral Therapy |
2020―Jun―04 |
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19 |
Xiangyang Xie, Yuanliang Jiang, Yuan Zeng, Hui Liu |